MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow, and it garners support from government and industry investments. MDWD has shown strong momentum, nearly doubling in price YTD, and is backed by a healthy mix of institutional and private investors.

MediWound Is A Healthy Investment

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Conference Call Participants Joshua Jennings - TD Cowen Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day and welcome to MediWound's Second Quarter 2024 Earnings Call.

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

MediWound (MDWD) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to earnings of $0.10 per share a year ago.

MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates

Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference C all T oday, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time

MediWound to Report Second Quarter 2024 Financial Results

The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?

Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs)

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE).

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment

MediWound Announces $25 Million Strategic Private Placement Financing

MediWound Ltd. (NASDAQ:MDWD ) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy, Corporate Development Daniel Ferry - Managing Director, LifeSci Advisors Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Operator Good day!

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

MediWound (MDWD) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago.

MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates

NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time

MediWound to Report First Quarter 2024 Financial Results

Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?

MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes MediWound (MDWD) a Good Fit for 'Trend Investing'

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound (MDWD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $1.18 per share a year ago.

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024 $42 million cash runway through profitability

News for MediWound Stock (MDWD)